There was a wonderful Q&A session with Dr. Schenk and Dr. Camidge on the 2022 ALK Summit in Denver. Colin Barton, (Member of our Medical Committee), has graciously taken the time to record the questions and occasions on the video recording that’s obtainable on our ALK Optimistic Youtube Channel.
0:50 When do you advocate consolidative remedy?
1:46 Ought to our tumor markers be monitored usually?
3:18 At what level are you able to scale back the frequency of scans?
5:03 What do you advocate when resistance to lorlatinib is happening?
7:04 Is there a trial for native consolidative remedy in Denver?
7:30 What ideas do you’ve for getting PET scans coated by insurance coverage?
7:51 When you have the TP53 mutation do you advocate to do something now?
9:06 If you’re NED on an ALK TKI would you advocate staying on the therapy or contemplate doing a medical trial earlier than resistance develops?
10:13 If you’re NED on an ALK TKI would you advocate doing LCT on lymph nodes the place most cancers was beforehand evident?
12:02 Are you able to discuss concerning the analysis you might be doing on blood primarily based immune signatures (eg lymphocytes, neutrophils, T cells, monocytes)?
15:16 I you’ve a pre-existing psychological well being dysfunction (eg bipolar) do you have to be involved about taking lorlatinib?
16:24 Have you ever ever had a stage 4 affected person that has benefited from surgical procedure
17:28 The place we reside oncologists don’t robotically do a biopsy upon development. What can we do about that?
18:50 What’s the significance of getting the reciprocal ALK EML4 translocation along with the usual EML4 translation?
19:32 What does it imply if an ALK mutation reveals up on a liquid biopsy whereas taking an ALK TKI?
20:48 How can we get extra collaboration between researchers at completely different establishments and corporations?
22:23 Would you ever revisit utilizing a TKI that you’ve got used earlier than?
23:04 Some medical doctors have urged utilizing the strongest ALK TKI obtainable up entrance (presently lorlatinib). If you’re doing effectively on an earlier technology ALK TKI, do you have to change to the lorlatinib?
24:28 Ought to we be requesting a liquid biopsy at common intervals to observe for development? If that’s the case, how typically?